JP2016504365A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504365A5
JP2016504365A5 JP2015550767A JP2015550767A JP2016504365A5 JP 2016504365 A5 JP2016504365 A5 JP 2016504365A5 JP 2015550767 A JP2015550767 A JP 2015550767A JP 2015550767 A JP2015550767 A JP 2015550767A JP 2016504365 A5 JP2016504365 A5 JP 2016504365A5
Authority
JP
Japan
Prior art keywords
aryl
compound
heterocyclyl
heteroaryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015550767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504365A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/077804 external-priority patent/WO2014105952A2/en
Publication of JP2016504365A publication Critical patent/JP2016504365A/ja
Publication of JP2016504365A5 publication Critical patent/JP2016504365A5/ja
Pending legal-status Critical Current

Links

JP2015550767A 2012-12-28 2013-12-26 Usp1/uaf1デユビキチナーゼ複合体阻害剤及びその使用 Pending JP2016504365A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261747052P 2012-12-28 2012-12-28
US61/747,052 2012-12-28
PCT/US2013/077804 WO2014105952A2 (en) 2012-12-28 2013-12-26 Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof

Publications (2)

Publication Number Publication Date
JP2016504365A JP2016504365A (ja) 2016-02-12
JP2016504365A5 true JP2016504365A5 (OSRAM) 2016-11-24

Family

ID=49958735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015550767A Pending JP2016504365A (ja) 2012-12-28 2013-12-26 Usp1/uaf1デユビキチナーゼ複合体阻害剤及びその使用

Country Status (6)

Country Link
US (1) US9802904B2 (OSRAM)
EP (1) EP2938610A2 (OSRAM)
JP (1) JP2016504365A (OSRAM)
AU (1) AU2013370417A1 (OSRAM)
CA (1) CA2896731A1 (OSRAM)
WO (1) WO2014105952A2 (OSRAM)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504365A (ja) 2012-12-28 2016-02-12 アメリカ合衆国 Usp1/uaf1デユビキチナーゼ複合体阻害剤及びその使用
MA41291A (fr) * 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶
WO2016126929A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
JP2018504432A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ7阻害物質としてのイソチアゾロピリミジノン、ピラゾロピリミジノン及びピロロピリミジノン
JP2018504430A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ7阻害物質としてのキナゾリノン及びアザキナゾリノン
JP6964343B2 (ja) * 2015-11-20 2021-11-10 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン
CN109071561B (zh) * 2016-02-12 2022-01-14 福马治疗股份有限公司 用作泛素特异性蛋白酶抑制剂的噻吩并吡嗪甲酰胺
US10913753B2 (en) 2016-02-12 2021-02-09 Valo Early Discovery, Inc. Thienopyridine carboxamides as ubiquitin-specific protease inhibitors
GB201604638D0 (en) * 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) * 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
KR102327053B1 (ko) * 2017-03-16 2021-11-17 기초과학연구원 퀴나졸린, 퀴놀린 유도체 및 egfr 키나제 억제제로서의 용도
KR101986013B1 (ko) * 2017-08-04 2019-06-04 연세대학교 산학협력단 Ml323을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
US11524966B1 (en) 2017-08-11 2022-12-13 Valo Health, Inc. Carboxamides as ubiquitin-specific protease inhibitors
EP3703669B1 (en) * 2017-11-01 2025-08-06 Dana-Farber Cancer Institute, Inc. Usp1 or uaf1 inhibitors for use in treating cancer
CA3108676A1 (en) 2018-08-09 2020-02-13 David J. Guerin Carboxamides as ubiquitin-specific protease inhibitors
JP2021534122A (ja) 2018-08-09 2021-12-09 ヴァロ アーリー ディスカバリー, インコーポレイテッド 脱ユビキチン化酵素usp25及びusp28の阻害
JP7662519B2 (ja) 2018-12-20 2025-04-15 ケーエスキュー セラピューティクス, インコーポレイテッド 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ1(usp1)阻害剤としてのそれらの使用
AU2020299526A1 (en) 2019-05-31 2022-01-20 Case Western Reserve University Bax inhibitors and uses thereof
CN110699453B (zh) * 2019-10-10 2020-09-01 山东大学第二医院 一种胆管癌检测、治疗和预后靶点及应用
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
IL302352A (en) 2020-10-30 2023-06-01 Ksq Therapeutics Inc Solid state forms of substituted pyrazolopyrimidines and uses thereof
CN114436976B (zh) * 2021-01-29 2023-07-11 石药集团中奇制药技术(石家庄)有限公司 一种新型喹唑啉类衍生物及其制备和应用
WO2022199652A1 (en) * 2021-03-24 2022-09-29 Impact Therapeutics (Shanghai) , Inc Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
TN2023000250A1 (en) * 2021-04-07 2025-07-02 Forma Therapeutics Inc Inhibiting ubiquitin-specific protease 1 (usp1)
CN113368112B (zh) * 2021-05-10 2022-09-27 河南农业大学 Usp1-uaf1抑制剂在制备药物中的应用,药物组合物
EP4430050A4 (en) 2021-11-12 2025-09-24 Insilico Medicine Ip Ltd SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 1 AND THEIR USES
CN119365460A (zh) 2022-04-08 2025-01-24 尚医治疗有限责任公司 与Ras超家族蛋白相互作用以用于治疗癌症、炎性疾病、RAS病和纤维化疾病的化合物
IL316542A (en) * 2022-04-29 2024-12-01 Jiangsu Yahong Meditech Co Ltd Pyrimidine compound, method for its preparation, and pharmaceutical use thereof
WO2024086790A1 (en) 2022-10-21 2024-04-25 Exelixis, Inc. 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS
CN120202201A (zh) * 2022-11-04 2025-06-24 深圳晶泰科技有限公司 泛素特异性蛋白酶1的抑制剂及其应用
WO2024153175A1 (en) * 2023-01-19 2024-07-25 Laekna Therapeutics Shanghai Co., Ltd. Heteroaromatic compounds and their use as usp1 inhibitors
WO2024233605A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
WO2024233665A1 (en) * 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
WO2025005744A1 (ko) * 2023-06-29 2025-01-02 (주)아이젠사이언스 신규 피리미딘 유도체
WO2025007840A1 (zh) * 2023-07-05 2025-01-09 江苏亚虹医药科技股份有限公司 联嘧啶化合物的晶型及其制备方法和用途
WO2025007777A1 (zh) * 2023-07-05 2025-01-09 江苏亚虹医药科技股份有限公司 嘧啶类化合物、其制备方法及其医药用途
WO2025010245A1 (en) 2023-07-06 2025-01-09 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
WO2025015905A1 (en) * 2023-07-14 2025-01-23 Laekna Therapeutics Shanghai Co., Ltd. Pyrimidine compounds and their use as usp1 inhibitors
WO2025102016A1 (en) * 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
WO2025129076A1 (en) * 2023-12-15 2025-06-19 Eikon Therapeutics, Inc. Pyridopyrimidine and quinazoline derivatives as usp1 inhibitors, compositions comprising them and methods of using the same
WO2025129135A2 (en) * 2023-12-15 2025-06-19 Eikon Therapeutics, Inc. Compositions comprising usp1 inhibitors and methods of using the same
WO2025151705A1 (en) 2024-01-10 2025-07-17 Vrise Therapeutics, Inc. Novel inhibitors of dna damage repair pathway

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 4−アミノキナゾリン誘導体およびそれを含有する医薬品
DE19853278A1 (de) 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE60204509T2 (de) 2001-04-20 2006-03-16 Ciba Speciality Chemicals Holding Inc. 4-Amino-2-(2-pyridinyl)pyrimidine als mikrobizide Wirksubstanzen
EP1254903B1 (en) 2001-04-20 2005-06-08 Ciba SC Holding AG 4-Amino-2-(pyridin-2-yl)pyrimidine as microbicidal active substances
WO2003026661A1 (fr) * 2001-09-14 2003-04-03 Yamanouchi Pharmaceutical Co., Ltd. Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine
MXPA04005510A (es) 2001-12-07 2006-02-24 Vertex Pharma Compuestos basados en pirimidina utiles como inhibidores de gsk-3.
CN1642422A (zh) * 2002-03-15 2005-07-20 西巴特殊化学品控股有限公司 4-氨基嘧啶及其在表面抗菌处理中的应用
JP4881558B2 (ja) * 2002-09-04 2012-02-22 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
US7820704B2 (en) * 2004-04-20 2010-10-26 Transtech Pharma, Inc. Substituted heteroaryl derivatives, compositions, and methods of use
CA2564996A1 (en) * 2004-05-08 2006-01-12 Taeyoung Yoon 3-aryl-5,6-disubstituted pyridazines
EP1844023A1 (en) 2004-12-31 2007-10-17 Sk Chemicals Co., Ltd. Quinazoline derivatives for the treatment and prevention of diabetes and obesity
US20070032499A1 (en) 2005-08-05 2007-02-08 Philippe Guedat Novel cysteine protease inhibitors and their therapeutic applications
MX2009003142A (es) * 2006-10-03 2009-04-06 Neurosearch As Derivados de indazolilo utiles como agentes moduladores del canal de potasio.
JP2010208945A (ja) * 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
WO2009011910A2 (en) 2007-07-18 2009-01-22 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Serices Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
JP2011032169A (ja) * 2007-12-11 2011-02-17 Genecare Research Institute Co Ltd 4−アミノピリミジン誘導体および該化合物を含有する医薬組成物
PH12012500097A1 (en) 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
AR077999A1 (es) * 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
CN102844313B (zh) 2010-01-28 2016-10-05 哈佛大学校长及研究员协会 提高蛋白酶体活性的组合物和方法
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2360158A1 (en) * 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
US9518032B2 (en) 2010-04-30 2016-12-13 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of USP1 deubiquitinating enzyme activity
US8865708B2 (en) 2010-05-07 2014-10-21 California Institute Of Technology Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase
WO2012012712A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Tricyclic proteasome activity enhancing compounds
CN103261169A (zh) 2010-09-24 2013-08-21 密歇根大学董事会 脱泛素酶抑制剂及其应用方法
WO2012061754A2 (en) 2010-11-05 2012-05-10 The Broad Institute, Inc. Compounds and methods for treating autoimmune diseases
WO2012172043A1 (en) * 2011-06-15 2012-12-20 Laboratoire Biodim Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
WO2013004332A1 (en) * 2011-07-07 2013-01-10 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
EP2546684A1 (fr) 2011-07-15 2013-01-16 ETA SA Manufacture Horlogère Suisse Guide de lumière pour l'éclairage d'un dispositif d'affichage d'informations
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
JP2014237590A (ja) 2011-09-30 2014-12-18 アステラス製薬株式会社 2−(ピリジン−2−イル)ピリミジン−4−アミン化合物又はその塩
KR102022575B1 (ko) 2011-10-19 2019-09-18 비보룩스 아베 탈유비퀴틴화 활성의 저해 방법
JP2015513317A (ja) 2012-01-25 2015-05-07 プロテオステイシス セラピューティクス,インコーポレイテッド プロテアソーム活性を増強する化合物
WO2013112651A2 (en) 2012-01-25 2013-08-01 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
JP2016504365A (ja) 2012-12-28 2016-02-12 アメリカ合衆国 Usp1/uaf1デユビキチナーゼ複合体阻害剤及びその使用

Similar Documents

Publication Publication Date Title
JP2016504365A5 (OSRAM)
JP2017531041A5 (OSRAM)
EA201201677A1 (ru) Производные гетероарилимидазолона в качестве ингибиторов jak
EA201200938A1 (ru) Производные имидазопиридина в качестве ингибиторов jak
NZ718487A (en) Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
RU2020102453A (ru) Фармацевтические композиции
EA201201143A1 (ru) Производные пиразола в качестве ингибиторов jak
PE20081888A1 (es) ANALOGOS DE PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE CINASA mTOR Y CINASA PI3
JP2014500870A5 (OSRAM)
EA201301319A1 (ru) Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний
JP2014508811A5 (OSRAM)
CO6290714A2 (es) Compuestos organicos
EA201400182A1 (ru) Производные пиридин-2(1н)-она в качестве ингибиторов jak
MX2013005008A (es) Derivados de carboxamida y urea heteroaromaticos sustituidos como ligandos del receptor vanilloide.
CL2008001230A1 (es) Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis.
JP2012153722A5 (OSRAM)
TN2016000014A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EA201000614A1 (ru) Производные пурина как лиганды аденозинового рецептора а
NZ590650A (en) Buprenorphine analogs
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
RU2015135722A (ru) Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение
MX2012013274A (es) Novedosos derivados de la pirimidina.
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
JP2017511321A5 (OSRAM)
RU2013141559A (ru) Способ ингибирования клеток опухоли гамартомы